Gelomics Awarded $948K Industry Growth Program Grant to Accelerate Commercialisation of AI-Powered 3D Tissue Culture Platform. 4 June 2025 Gelomics is proud to announce the award of $948,066 in non-dilutive grant funding through the Industry Growth Program under the Commercialisation and Growth stream. The $1.9 million project will fast-track the commercialisation of Gelomics’ next-generation AI-assisted […]
Gelomics Partners with SLS to Expand 3D Tissue Culture Access Across the UK and Ireland Gelomics is proud to announce a strategic distribution partnership with Scientific Laboratory Supplies (SLS), the United Kingdom’s largest independent supplier of laboratory products. Under this agreement, SLS will serve as Gelomics’ exclusive distributor in the UK and Ireland, significantly expanding […]
Gelomics Expands Global Presence with New Distribution Partner, Voden Medical In Italy Gelomics proudly announces a strategic partnership with Voden Medical. Voden Medical is a renowned provider of advanced diagnostic and life science solutions in Italy. Under this agreement, Voden Medical will serve as Gelomics’ exclusive distributor in the Italian market. This partnership, effective January […]
Conference | Join Gelomics at AACR 2025 in Chicago We’re excited to showcase our latest innovations in 3D cell culture at AACR this April. If you’re attending, let’s connect! Schedule a meeting with our team to explore how our technology can accelerate your cancer research. 📅 April 25-30, 2025 📍 Booth #444, McCormick Place Convention Center Chicago, […]
On-demand Seminar | LunaGel™ Transforming 3D Cell Culture for Biomedical Breakthroughs Discover the future of biomedical research with LunaGel™, an innovative 3D cell culture platform by Gelomics. Join Dr. Christoph Meinert, CEO of Gelomics, for an exclusive seminar exploring how LunaGel™ is revolutionizing the creation of realistic human tissue models—bridging the gap between traditional cell […]
Gelomics partners with Bucher Biotec AG for Product Distribution in Switzerland Gelomics is pleased to announce a new strategic partnership with Bucher Biotec AG, a leading provider of advanced life science solutions in Switzerland & Lichtenstein. Under this agreement, Bucher Biotec will serve as Gelomics’ exclusive distributor across the Swiss market. This partnership marks an […]
Gelomics announces appointment of Distinguished Professor Dietmar W. Hutmacher, PhD, MBA and Professor Travis J. Klein, PhD to its Scientific Advisory Board Gelomics, a leading Australian biotech firm at the forefront of drug development innovation, is further strengthening its Scientific Advisory Board with the addition of Distinguished Professor Dietmar W. Hutmacher, PhD, MBA, and Professor […]
LunaGel™ Ultrapure GelMA ECM Is Now Available We’re thrilled to unveil our latest innovation! LunaGel™ Ultrapure GelMA Photocrosslinkable Extracellular Matrix (ECM), now available in both High Stiffness and Low Stiffness options. Developed in collaboration with Rousselot Biomedical, this breakthrough leverages the advanced X-Pure® GelMA technology, setting a new standard for 3D cell culture by offering […]
